Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak.
